Dosing has commenced in BioNTech's BNT111 Phase II cancer vaccine trial in advanced melanoma.
Positive first results from the CheckMate-648 trial suggests a new potential standard of care in the first line for advanced oesophagal squamous cell carcinoma (ESCC).
LoA Update: BMS’ Opdivo/relatlimab combination gets boost in approval likelihood in 1L melanoma after Phase II/III results at ASCO
The Likelihood of Apporval (LoA) for Bristol Myers Squibb’s Opdivo (nivolumab) combo with the anti-LAG3 antibody relatlimab climbed by 10 points to 49%, as of 9 June.
LoA Update: Amgen’s bemarituzumab approval likelihood in gastroesophageal junction and gastric cancers jumps after Phase II ASCO reveal
Amgen’s bemarituzumab had its Likelihood of Approval (LoA) jump by 9 points and 5 points in first-line (1L) gastroesophageal junction (GEJ) and gastric cancer, respectively, as of 10 June.